Advertisement

A Patient with Differentiated Thyroid Cancer with Tg Values Constantly Above Normal but Not Increasing Gradually

  • Çiğdem Soydal
  • Elgin Özkan
Chapter

Abstract

A 46-year-old female patient with an euthyroid multinodular goiter underwent fine needle aspiration biopsy because ultrasound examination indicated a thyroid malignancy. In the postoperative evaluation of thyroidectomy material, a papillary thyroid carcinoma was detected in the right thyroid lobe with a maximum 2.2 cm diameter (T2N0Mx). The patient received radioiodine ablation treatment with 3700 MBq (100 mCi) iodine-131. Six months after RAT, diagnostic whole-body scintigraphy was performed with 185 MBq (5 mCi) I-131. Serum-stimulated Tg levels were 3.47 ng/mL, and I-131 scintigraphy results were normal. Neck ultrasound and computed tomography of the thorax were performed to search possible recurrent disease. There was no cervical lymph node or lung metastases.

Keywords

Papillary thyroid carcinoma Thyroglobulin Indeterminate response 

References

  1. 1.
    Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2015;2016(26):1–159.  https://doi.org/10.1089/thy.2015.0020.CrossRefGoogle Scholar
  2. 2.
    Matthews TJ, Chua E, Gargya A, Clark J, Gao K, Elliott M. Elevated serum thyroglobulin levels at the time of ablative radioactive iodine therapy indicate a worse prognosis in thyroid cancer: an Australian retrospective cohort study. J Laryngol Otol. 2016;130(Suppl 4):50–3.  https://doi.org/10.1017/S0022215116008331.CrossRefGoogle Scholar
  3. 3.
    Miyauchi A, Kudo T, Miya A, Kobayashi K, Ito Y, Takamura Y, et al. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid. 2011;21:707–16.  https://doi.org/10.1089/thy.2010.0355.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, et al. Estimating the risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20:1341–9.  https://doi.org/10.1089/thy.2010.0178.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Park S, Kim WG, Song E, Oh HS, Kim M, Kwon H, et al. Dynamic risk stratification for predicting recurrence in patients with differentiated thyroid cancer treated without radioactive iodine remnant ablation therapy. Thyroid. 2017;27:524–30.  https://doi.org/10.1089/thy.2016.0477.CrossRefPubMedGoogle Scholar
  6. 6.
    Morosán YJ, Parisi C, Urrutia MA, Rosmarin M, Schnitman M, Serrano L, et al. Dynamic prediction of the risk of recurrence in patients over 60 years of age with differentiated thyroid carcinoma. Arch Endocrinol Metab. 2016;60:348–54.  https://doi.org/10.1590/2359-3997000000146.CrossRefPubMedGoogle Scholar
  7. 7.
    Omry-Orbach G. Risk stratification in differentiated thyroid cancer: an ongoing process. Rambam Maimonides Med J. 2016;28:7.  https://doi.org/10.5041/RMMJ.CrossRefGoogle Scholar
  8. 8.
    Vaisman F, Momesso D, Bulzico DA, Pessoa CH, Dias F, et al. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin Endocrinol. 2012;77:132–8.  https://doi.org/10.1111/j.1365-2265.2012.04342.x.CrossRefGoogle Scholar
  9. 9.
    Durante C, Montesano T, Attard M, Torlontano M, Monzani F, Costante G, PTC Study Group, et al. Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement? J Clin Endocrinol Metab. 2012;97:2748–53.  https://doi.org/10.1210/jc.2012-1123.CrossRefPubMedGoogle Scholar
  10. 10.
    Dercle L, Deandreis D, Terroir M, Leboulleux S, Lumbroso J, Schlumberger M. Evaluation of (124)I PET/CT and (124)I PET/MRI in the management of patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2016;43:1006–10.  https://doi.org/10.1007/s00259-016-3334-4.CrossRefPubMedGoogle Scholar
  11. 11.
    Santhanam P, Taieb D, Solnes L, Marashdeh W, Ladenson PW. Utility of I 124 PET/CT in identifying radioiodine avid lesions in differentiated thyroid cancer; a systematic review and meta-analysis. Clin Endocrinol. 2017;86:645–51.  https://doi.org/10.1111/cen.13306.CrossRefGoogle Scholar
  12. 12.
    Kuker R, Sztejnberg M, Gulec S. I-124 imaging, and dosimetry. Mol Imaging Radionucl Ther. 2016;5:66–73.  https://doi.org/10.4274/2017.26.CrossRefGoogle Scholar
  13. 13.
    Binse I, Poeppel TD, Ruhlmann M, Gomez B, Umutlu L, Bockisch A, et al. Imaging with (124) I in differentiated thyroid carcinoma: is PET/MRI superior to PET/CT? Eur J Nucl Med Mol Imaging. 2016;43:1011–7.  https://doi.org/10.1007/s00259-015-3288-y.CrossRefPubMedGoogle Scholar
  14. 14.
    Vrachimis A, Burg MC, Wenning C, Allkemper T, Weckesser M, Schäfers M, et al. [(18)F]FDG PET/CT outperforms [(18)F]FDG PET/MRI in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2016;43:212–20.  https://doi.org/10.1007/s00259-015-3195-2.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Çiğdem Soydal
    • 1
  • Elgin Özkan
    • 2
  1. 1.Department of Nuclear MedicineAnkara University School of MedicineAnkaraTurkey
  2. 2.Department of Nuclear MedicineMedical Faculty of Ankara UniversityAnkaraTurkey

Personalised recommendations